GlobeNewswire·Oct 31, 2025, 3:00 AM ET

NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth

Nanobiotix secured up to $71 million in non-dilutive capital through a royalty-based financing agreement with HealthCare Royalty (HCRx)
The transaction provides an upfront payment of $50 million at closing with a potential additional $21 million tranche one year post-closing subject to conditions
Funding extends Nanobiotix cash runway into early 2028 to advance development of head & neck cancer (NANORAY-312) & lung cancer (CONVERGE) programs
HCRx will receive a capped portion of milestones & royalties on JNJ-1900 (NBTXR3) sales payable to Nanobiotix under its global licensing agreement
Repayment to HCRx is capped at approximately $124 million (1.75x MOIC) if completed by end of 2030, or approximately $178 million (2.50x MOIC) if completed thereafter
A royalty-only tail period will commence after the Return Cap is met, entitling HCRx to a reduced share of royalties not exceeding $14.9 million annually for 10 years following the first US commercial sale
Payment obligations will be fulfilled via transfer of receivables from the JNJ-1900 license agreement to a French law trust
JNJ-1900 (NBTXR3) is a radiotherapy-activated hafnium oxide nanoparticle in Phase 3 trials for locally advanced head & neck squamous cell cancers
TD Cowen served as the sole financial advisor to Nanobiotix for this transaction
The financing establishes a financial foundation toward self-sustainability & the advancement of next-generation nanotherapeutic platforms